A bacillus-based coxsackie virus A16 mucosal vaccine induces strong neutralizing antibody responses

Yin Guang Cao, Yu Hao, Lexin Wang

Research output: Contribution to journalArticle

5 Downloads (Pure)

Abstract

The purpose of this study was to construct a Coxsackie virus A16 (CA16) mucosal vaccine and evaluate its ability to induce immune response. VP1 gene of CA16 was inserted into the genome of Bacillus subtilis via recombination and displayed on the surface of the spores. This Bacillus-based vaccine was used for intranasal immunization of mice and the serum antibody titer was determined by enzyme-linked immunosorbent assay (ELISA). Neutralization activity of the serum from immunized mice was analyzed by an in vitro neutralizing test. VP1 gene was successfully integrated into the genome of Bacillus subtilis and was expressed on the surface of Bacillus spores. Intranasal immunization of mice with this vaccine induced a higher level of VP1 specific IgA and IgG than in mice of the control group (p < 0.05). The neutralizing antibody titer in the spore immunization group was 1: 169, which was higher than that in the control group (p < 0.05). We concluded that vaccine prepared by displaying CA16 VP1 protein on the surface of Bacillus subtilis spores can stimulate mice to produce protective neutralizing antibodies, which provides foundations for the development of CA16 mucosal vaccine.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalCentral European Journal of Immunology
Volume44
Issue number1
DOIs
Publication statusPublished - 01 Jan 2019

Fingerprint

Enterovirus
Neutralizing Antibodies
Bacillus
Antibody Formation
Spores
Vaccines
Bacillus subtilis
Immunization
Genome
Control Groups
Serum
Immunoglobulin A
Genetic Recombination
Genes
Membrane Proteins
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Antibodies

Cite this

@article{a13ee7a241814223a2f2f3d517ac90bf,
title = "A bacillus-based coxsackie virus A16 mucosal vaccine induces strong neutralizing antibody responses",
abstract = "The purpose of this study was to construct a Coxsackie virus A16 (CA16) mucosal vaccine and evaluate its ability to induce immune response. VP1 gene of CA16 was inserted into the genome of Bacillus subtilis via recombination and displayed on the surface of the spores. This Bacillus-based vaccine was used for intranasal immunization of mice and the serum antibody titer was determined by enzyme-linked immunosorbent assay (ELISA). Neutralization activity of the serum from immunized mice was analyzed by an in vitro neutralizing test. VP1 gene was successfully integrated into the genome of Bacillus subtilis and was expressed on the surface of Bacillus spores. Intranasal immunization of mice with this vaccine induced a higher level of VP1 specific IgA and IgG than in mice of the control group (p < 0.05). The neutralizing antibody titer in the spore immunization group was 1: 169, which was higher than that in the control group (p < 0.05). We concluded that vaccine prepared by displaying CA16 VP1 protein on the surface of Bacillus subtilis spores can stimulate mice to produce protective neutralizing antibodies, which provides foundations for the development of CA16 mucosal vaccine.",
keywords = "Bacillus subtilis, Coxsackie virus A16, Foot, Genes, Hand, Mouth disease, Mucosa vaccine, VP1",
author = "Cao, {Yin Guang} and Yu Hao and Lexin Wang",
year = "2019",
month = "1",
day = "1",
doi = "10.5114/ceji.2019.84009",
language = "English",
volume = "44",
pages = "1--6",
journal = "Central-European Journal of Immunology",
issn = "1426-3912",
publisher = "Termedia Publishing House Ltd.",
number = "1",

}

A bacillus-based coxsackie virus A16 mucosal vaccine induces strong neutralizing antibody responses. / Cao, Yin Guang; Hao, Yu; Wang, Lexin.

In: Central European Journal of Immunology, Vol. 44, No. 1, 01.01.2019, p. 1-6.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A bacillus-based coxsackie virus A16 mucosal vaccine induces strong neutralizing antibody responses

AU - Cao, Yin Guang

AU - Hao, Yu

AU - Wang, Lexin

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The purpose of this study was to construct a Coxsackie virus A16 (CA16) mucosal vaccine and evaluate its ability to induce immune response. VP1 gene of CA16 was inserted into the genome of Bacillus subtilis via recombination and displayed on the surface of the spores. This Bacillus-based vaccine was used for intranasal immunization of mice and the serum antibody titer was determined by enzyme-linked immunosorbent assay (ELISA). Neutralization activity of the serum from immunized mice was analyzed by an in vitro neutralizing test. VP1 gene was successfully integrated into the genome of Bacillus subtilis and was expressed on the surface of Bacillus spores. Intranasal immunization of mice with this vaccine induced a higher level of VP1 specific IgA and IgG than in mice of the control group (p < 0.05). The neutralizing antibody titer in the spore immunization group was 1: 169, which was higher than that in the control group (p < 0.05). We concluded that vaccine prepared by displaying CA16 VP1 protein on the surface of Bacillus subtilis spores can stimulate mice to produce protective neutralizing antibodies, which provides foundations for the development of CA16 mucosal vaccine.

AB - The purpose of this study was to construct a Coxsackie virus A16 (CA16) mucosal vaccine and evaluate its ability to induce immune response. VP1 gene of CA16 was inserted into the genome of Bacillus subtilis via recombination and displayed on the surface of the spores. This Bacillus-based vaccine was used for intranasal immunization of mice and the serum antibody titer was determined by enzyme-linked immunosorbent assay (ELISA). Neutralization activity of the serum from immunized mice was analyzed by an in vitro neutralizing test. VP1 gene was successfully integrated into the genome of Bacillus subtilis and was expressed on the surface of Bacillus spores. Intranasal immunization of mice with this vaccine induced a higher level of VP1 specific IgA and IgG than in mice of the control group (p < 0.05). The neutralizing antibody titer in the spore immunization group was 1: 169, which was higher than that in the control group (p < 0.05). We concluded that vaccine prepared by displaying CA16 VP1 protein on the surface of Bacillus subtilis spores can stimulate mice to produce protective neutralizing antibodies, which provides foundations for the development of CA16 mucosal vaccine.

KW - Bacillus subtilis

KW - Coxsackie virus A16

KW - Foot

KW - Genes

KW - Hand

KW - Mouth disease

KW - Mucosa vaccine

KW - VP1

UR - http://www.scopus.com/inward/record.url?scp=85064855075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064855075&partnerID=8YFLogxK

U2 - 10.5114/ceji.2019.84009

DO - 10.5114/ceji.2019.84009

M3 - Article

C2 - 31114430

AN - SCOPUS:85064855075

VL - 44

SP - 1

EP - 6

JO - Central-European Journal of Immunology

JF - Central-European Journal of Immunology

SN - 1426-3912

IS - 1

ER -